
    
      To test whether bendamustine will improve progression-free survival in subjects with indolent
      B-cell NHL that did not respond (stable disease or progressive disease) to rituximab or a
      rituximab-containing regimen during or within 6 months of the last rituximab treatment
      compared to treatment of physican's choice.
    
  